The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation

Thoracic and Cardiovascular Surgeon

Volumn 45, Issue 4, 1997, Pages 190-195

  Aleksic, I ^a   Freimark, D ^c   Blanche, C ^b   Czer, L S C ^c   Dalichau, H ^a   Valenza, M ^b   Takkenberg, J J M ^c   Trento, A ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Division of Cardiothoracic Surgery

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Heart transplantation; Induction therapy; OKT3

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; PREDNISONE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHILL; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FEVER; GRAFT REJECTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RASH; SURGICAL TECHNIQUE;

EID: 0030882220     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1013721     Document Type: Article

References (33)

1. Aleksic, I., L. S. C. Czer, D. Freimark, H. Dalichau, J. J. M. Takkenberg, C. Blanche, S. Nessim, P. Nusser, and A. Trento: Heart transplantation in patients with diabetic end-organ damage before transplantation. Thorac. cardiovasc. Surgeon 44 (1996) 282-288
2. Alloway, E., K. Kotb, D. K. Hathaway, L. W. Gaber, S. R. Vera, and A. O. Gaber: Randomized double-blind study of standard versus low-dose OKT3 induction therapy in renal allograft recipients. Am. J. Kidney Dis. 22 (1993) 36-43
3. Barr, M. L., J. A. Sanchez, L. A. Seche, L. L. Schulman, C. R. Smith, and E. A. Rose: Anti-CD3 monoclonal antibody induction therapy. Circulation 82 (1990) Suppl. V: 291-294
4. Billingham, M. E., N. R. B. Cary, E. H. Hammond, J. Kemnitz, C. Marboe, H. A. McCallister, D. C. Snovar, C. L. Winter, and A. Zerbe: A working formulation for standardization of the nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J. Heart Transplant. 9 (1990) 587-593
5. Blanche, C., M. Valenza, L. S. C. Czer, P. Barath, D. Admon, D. A. Harasty, C. Utley, D. Freimark, I. Aleksic, J. M. Matloff, and A. Trento: Orthotopic heart transplantation with total excision of recipient's atria, bicaval and pulmonary venous anastomoses: Clinical experience and early results. Ann. Thorac. Surg. 58 (1994) 1505-1509
6. Blanche, C., J. J. M. Takkenberg, S. Nessim, M. Cohen, L. S. C. Czer, J. Matloff, and A. Trento: Heart transplantation in patients 65 years of age and older: a comparative analysis of 40 patients. Ann. Thorac. Surg. 62 (1996) 1442-1447
7. BMDP Statistical Software Manual, 1990 Revision, Volume 2. Berkeley Calif, University of California Press, 1990
8. Carrier, M., M. Jenicek, and L. C. Pelletier: Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis. Transplant Proc. 24 (1992) 2586-2591
9. Costanzo-Nordin, M. R., E. J. O'Sullivan, M. R. Johnson, G. L. Winters, R. Pifarre, R. Radvany, M. J. Zucker, P. J. Scanlon, and J. A. Robinson: Prospective randomized trial of OKT3 versus antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J. Heart Transplant. 9 (1990) 306-315
10. Costanzo-Nordin, M. R., M. A. Silver, J. B. O'Connell, R. Pifarre, K. L. Grady, G. L. Winters, D. K. Murdock, H. J. Sullivan, J. G. Grieco, P. J. Scanlon, and J. A. Robinson: Successful reversal of acute cardiac allograft rejection with OKT3 monoclonal antibody. Circulation 76 (1987) V71-V80
11. Dreyfus, G., V. Jebara, S. Mihaileanu, and A. F. Carpentier: Total orthotopic heart transplantation: an alternative to the standard technique. Ann. Thorac. Surg. 52 (1991) 1181-1184
12. Gilbert, E. M., C. W. DeWitt, C. C. Eiswirth, D. C. Renlund, R. L. Menlove, L. A. Freedman, C. M. Herrick, W. A. Gay, and M. R. Bristow: Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am. J. Med. 82 (1987) 202-206
13. Griffith, B. P., R. L. Kormos, J. M. Armitage, J. S. Dummer, and R. L. Hardesty: Comparative trial of immunoprophylaxis with RATG versus OKT3. J. Heart Transplant. 9 (1990) 301-305
14. Hammond, E. H., R. L. Yowell, S. Nunoda, R. L. Menlove, D. G. Renfund, M. R. Bristow, W. A. Gay, K. W. Jones, J. B. O'Connell: Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J. Heart Transplant. 8 (1989) 430-443
15. Haverty, T. P., M. Sanders, and M. Sheahan: OKT3 treatment of cardiac allograft rejection. J. Heart Lung Transplant. 12 (1993) 591-598
16. Hegewald, M. G., J. B. O'Connell, D. G. Renlund, H. R. Lee, N. A. Nurton, S. V. Karvande, K. W. Jones, J. E. Lassetter, and M. R. Bristow: OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis after heart transplantation. J. Heart Transplant. 8 (1989) 303-310
17. Johnson, M. R., G. M. Mullen, E. J. O'Sullivan, Y. Liao, A. L. Heroux, W. G. Kao, R. Pifarre, and M. R. Costanzo: Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am. J. Cardiol. 74 (1994) 261-266
18. Kirklin, J. K., R. C. Bourge, C. White-Williams, D. C. Naftel, F. T. Thomas, J. M. Thomas, and M. G. Phillips: Prophylactic therapy for rejection after cardiac transplantation. J. Thorac. Cardiovasc. Surg. 99 (1990) 716-724
19. Kobashigawa, J. A., L. W. Stevenson, E. Brownfield, J. D. Moriguchi, N. Kawata, M. Hamilton, R. Minkely, D. Drinkwater, and H. Laks: Does short-course induction with OKT3 improve outcome after heart transplantation? A randomized trial. J. Heart Lung. Transplant. 12 (1993) 200-208
20. Loebe, M., S. Schüler, O. Zais, H. Warnecke, E. Fleck, and R. Hetzer: Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J. Heart Transplant. 9 (1990) 707-711
21. McDonald, K., T. S. Rector, E. A. Braunlin, S. H. Kubo, and M. T. Olivari: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am. J. Cardiol. 64 (1989) 359-362
22. Miller, L. W., R. C. Schlant, J. Kobashigawa, S. Kubo, and D. G. Renlund: Task force 5: complications. J. Am. Coll. Cardiol. 22 (1993) 41-54
23. Norman, D. J., J. M. Barry, W. M. Bennett, J. L. Munson, M. Meyer, K. Henell, K. Kimball, and B. Hubert: OKT3 for induction immunosuppression in renal transplantation: A comparative study of high versus low doses. Transplant. Proc. 23 (1991) 1052-1054
24. Oh, C. S., R. J. Stratta, B. C. Fox, H. W. Sollinger, F. O. Belzer, and D. G. Maki: Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 45 (1988) 68-73
25. Prieto, M., K. D. Lake, M. R. Pritzker, C. R. Jorgensen, K. V. Arom, K. R. Love, and R. W. Emery: OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. J. Heart Lung Transplant. 10 (1991) 901-911
26. Renlund, D. G., J. B. O'Connell, and M. R. Bristow: Early rejection therapy in heart transplantation: is cytolytic therapy necessary? J. Heart Transplant. 8 (1989) 191-193
27. Renlund, D. G., J. B. O'Connell, E. M. Gilbert, E. Hammond, N. A. Burton, K. W. Jones, S. V. Karvande, D. B. Doty, R. L. Menlove, C. M. Herrick, H. R. Lee, W. A. Gay, and M. R. Bristow: A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Transplantation 47 (1989) 599-605
28. Renlund, D. G., J. B. O'Connell, E. M. Gilbert, F. S. Watson, and M. R. Bristow: Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J. Heart Transplant. 6 (1987) 71-78
29. Starnes, V. A., P. E. Oyer, E. B. Stinson, J. R. Dein, and N. E. Shumway: Prophylactic OKT3 used as induction therapy for heart transplantation. Circulation 80 (1989) III 79-III 83
30. Sweeney, M. S., J. T. Sinnott, J. P. Cullison, and S. S. Weinstein: The use of OKT3 for stubborn heart allograft rejection: an advance in clinical immunotherapy? J. Heart Transplant. 6 (1987) 324-328
31. Swinnen, L. J., M. R. Costanzo-Nordin, S. G. Fisher, E. J. O'Sullivan, M. R. Johnson, A. L. Heroux, G. J. Dizikes, R. Pifarre, and R. I. Fisher: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N. Engl. J. Med. 323 (1990) 1723-1728
32. Toyoda, M., K. Galfayan, K. Wachs, L. S. C. Czer, and S. C. Jordan: Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. Clin. Transplant 9 (1995) 472-480
33. Wollenek, G., G. Laufer, A. Laczkovics, P. Buxbaum, and I. Kober: Comparison of a monoclonal anti-T-cell antibody vs ATG as prophylaxis after heart transplantation. Transplant. Proc. 21 (1989) 2499-2501